AbbVie (ABBV) Operating Expenses (2012 - 2026)
AbbVie (ABBV) reported Operating Expenses of $11.0 billion for Q1 2026, up 14.59% year-over-year from $9.6 billion in Q1 2025, and down 8.8% on a QoQ basis from $12.1 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Operating Expenses data on file, last reported at $11.0 billion in Q1 2026.
- Quarterly Operating Expenses rose 14.59% year-over-year to $11.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.5 billion (changed 0.41% YoY) and the FY2025 annual result came in at $46.1 billion, down 2.36% from the prior year.
- Operating Expenses retreated to $11.0 billion in Q1 2026 per ABBV's latest filing, from $12.1 billion in the prior quarter.
- Across five years, Operating Expenses topped out at $16.6 billion in Q4 2024 and bottomed at $8.8 billion in Q1 2022.
- The 5-year median for Operating Expenses is $10.5 billion (2025), against an average of $10.9 billion.
- The widest annual swing landed in 2024, when Operating Expenses soared 49.4%; it then dropped 27.23% in 2025.
- Tracing ABBV's Operating Expenses over 5 years: stood at $9.6 billion in 2022, then gained by 15.46% to $11.1 billion in 2023, then soared by 49.4% to $16.6 billion in 2024, then declined by 27.23% to $12.1 billion in 2025, then fell by 8.8% to $11.0 billion in 2026.
- Per Business Quant, the three latest ABBV Operating Expenses figures stand at $11.0 billion (Q1 2026), $12.1 billion (Q4 2025), and $13.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 6.72 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 9.59 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 11.01 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 19.82 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 5.95 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 4.37 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 5.50 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 8.25 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.01 Bn |
| Dec 31, 2025 | 12.07 Bn |
| Sep 30, 2025 | 13.87 Bn |
| Jun 30, 2025 | 10.53 Bn |
| Mar 31, 2025 | 9.61 Bn |
| Dec 31, 2024 | 16.59 Bn |
| Sep 30, 2024 | 10.63 Bn |
| Jun 30, 2024 | 10.46 Bn |
| Mar 31, 2024 | 9.51 Bn |
| Dec 31, 2023 | 11.11 Bn |
| Sep 30, 2023 | 11.65 Bn |
| Jun 30, 2023 | 9.35 Bn |
| Mar 31, 2023 | 9.46 Bn |
| Dec 31, 2022 | 9.62 Bn |
| Sep 30, 2022 | 10.21 Bn |
| Jun 30, 2022 | 11.29 Bn |
| Mar 31, 2022 | 8.82 Bn |
| Dec 31, 2021 | 9.81 Bn |
| Sep 30, 2021 | 10.04 Bn |
| Jun 30, 2021 | 9.52 Bn |
| Mar 31, 2021 | 8.91 Bn |
| Dec 31, 2020 | 10.11 Bn |
| Sep 30, 2020 | 9.65 Bn |
| Jun 30, 2020 | 9.67 Bn |
| Mar 31, 2020 | 5.02 Bn |
| Dec 31, 2019 | 4.75 Bn |
| Sep 30, 2019 | 5.86 Bn |
| Jun 30, 2019 | 4.86 Bn |
| Mar 31, 2019 | 4.82 Bn |
| Dec 31, 2018 | 10.75 Bn |
| Sep 30, 2018 | 5.08 Bn |
| Jun 30, 2018 | 5.52 Bn |
| Mar 31, 2018 | 5.03 Bn |
| Dec 31, 2017 | 5.96 Bn |
| Sep 30, 2017 | 4.30 Bn |
| Jun 30, 2017 | 4.28 Bn |
| Mar 31, 2017 | 4.13 Bn |
| Dec 31, 2016 | 4.48 Bn |
| Sep 30, 2016 | 4.07 Bn |
| Jun 30, 2016 | 4.07 Bn |
| Mar 31, 2016 | 3.68 Bn |
| Dec 31, 2015 | 4.29 Bn |
| Sep 30, 2015 | 4.06 Bn |
| Jun 30, 2015 | 3.62 Bn |
| Mar 31, 2015 | 3.35 Bn |
| Dec 31, 2014 | 5.87 Bn |
| Sep 30, 2014 | 4.06 Bn |
| Jun 30, 2014 | 3.41 Bn |
| Mar 31, 2014 | 3.21 Bn |
| Dec 31, 2013 | 3.58 Bn |
| Sep 30, 2013 | 3.29 Bn |
| Jun 30, 2013 | 3.24 Bn |
| Mar 31, 2013 | 3.02 Bn |
| Dec 31, 2012 | 3.39 Bn |
| Sep 30, 2012 | 2.91 Bn |
| Jun 30, 2012 | 3.07 Bn |
| Mar 31, 2012 | 3.20 Bn |